Hepatopancreatobiliary Surgery Institute of Gansu Province
Lanzhou, Gansu, 730000, China
NCT Number: NCT03104582
To investigate the biliary drainage-related cholangitis and other complications of percutaneous transhepatic biliary drainage (PTBD) in the management of Klatskin tumor (KT) compared with endoscopic biliary drainage (EBD).
Looking for future studies?
Notify Me18 year–90 year
All sexes
Interventional
Not applicable
Lanzhou, Gansu, 730000, China
Operative treatment combined with preoperative biliary drainage (PBD) has been established as a safe management strategy for KT. Preoperative cholangitis was an independent risk factor for patients undergoing resection for KT. However, controversy exists regarding the preferred technique for PBD.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
When advanced Klatskin Tumor patients need biliary drainage, they choose to perform endoscopic drainage after informed consent.
When advanced Klatskin Tumor patients need biliary drainage, they choose to perform percutaneous transhepatic biliary drainage after informed consent.
Time frame: 2 weeks
Acute cholangitis is defined if patients experienced abdominal pain, high fever, or chill after procedure in 2 weeks
Time frame: 2 weeks
Pain score (scores:1-10)
Time frame: 6 months
The total time of hospital stay
Time frame: 6 months
Pancreatitis, bleeding, perforation, seeding
Hepatopancreatobiliary Surgery Institute of Gansu Province
Other
Best Biliary Drainage Option in Type II、III、IV Klatskin Tumor:ERCP or PTBD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03104569
Adenocarcinoma, Bile Duct Diseases
Lanzhou, Gansu, China
View Trial DetailsNCT05750966
Bile Duct Diseases, Biliary Tract Diseases
Almere Stad, Flevoland, Netherlands
View Trial DetailsNCT05225909
Bile Duct Diseases, Biliary Tract Diseases
Nottingham, United Kingdom
View Trial DetailsNCT06111872
Bile Duct Diseases, Biliary Tract Diseases
Cheras, Kuala Lumpur, Malaysia
View Trial Details